Today's Edition
A. SREENIVASA REDDY (ABU DHABI)
Mubadala, the Abu Dhabi-based sovereign investor, has announced additional investment in PCI Pharma Services, a global leader in contract development and manufacturing (CDMO) for complex biologics and innovative therapies.
The investment is being made alongside private equity firms Bain Capital, Kohlberg, and existing investor Partners Group.
The strategic transaction will see PCI enter its next phase of growth with support from this strong consortium of global investors. While financial terms were not disclosed, the partnership is expected to accelerate PCI’s global expansion and bolster its capabilities in biopharma services.
In a post on X, Mubadala stated: “This marks our continued support of PCI, following our initial commitment in 2020. Over the past five years, the company has demonstrated the strength of its global capabilities and its role in advancing innovation to improve patient access and outcomes.”
Mina Hamoodi, Head of Healthcare at Mubadala, commented: “Our reinvestment in PCI reflects our deep conviction in the company’s mission, leadership, and long-term potential. At this important juncture, we are delighted to welcome Bain Capital, an industry-leading healthcare investor with deep expertise in growing pharma services businesses, as a partner.”
She added: “We look forward to partnering with Bain and Kohlberg, and working closely with PCI’s outstanding management team, as the company enters its next chapter of accelerated growth.”
Partners Group will also continue to support PCI with a minority investment. Sujit John, Managing Director, Private Equity Health & Life at Partners Group, said: "PCI's market position, reputation, and world-class capabilities strategically position the Company to be the partner of choice for customers. We look forward to supporting PCI and the new ownership group in driving the Company into its next phase of growth.”
Headquartered in Philadelphia, PCI has over 7,500 employees across 38 sites in seven countries.
The company offers integrated services across the entire drug development lifecycle, and its continued investments in sterile injectables and high-potency manufacturing will strengthen pharmaceutical supply chains in the US and beyond.
